Nadim Ahmed, ​President and ​CEO of Cullinan Oncology, a clinical-stage biotechnology company developing a diversified pipeline of potential first​ ​- and best-in-class targeted therapies for patients with cancer, discusses his perspective on the future of the oncology treatment landscape, as well as what Cullinan Oncology is specifically doing for patients with unmet needs and to advance its diverse portfolio of differentiated oncology assets.

Nadim has more than twenty-five years of leadership experience in oncology across a range of development and commercialization roles, including recently at Bristol Myers Squibb (BMS), where he served as President, Hematology and at Celgene Corporation (Celgene) where he served as President, Global Hematology & Oncology through its acquisition by BMS. As President, Hematology at BMS, Nadim oversaw multiple product launches and participated as a member of the company’s Leadership Team. Prior to BMS, Nadim served in leadership roles at Celgene across both development and commercialization functions. During this time at Celgene, he successfully launched multiple cancer medicines, including Pomalyst ®, Abraxane ® and several key indications for Revlimid ®. Nadim has worked with various treatment modalities, including small molecules, biologics and cell therapy in hematology and solid tumors. Nadim holds a Master of Science degree from Loughborough University, UK and a Bachelor of Science degree from University College London, UK.

Nadim currently serves on the Board of Directors for Family Promise, a national non-profit organization helping homeless families.

Liked it? Take a second to support healthprofessionalradio on Patreon!